• Most Popular
  • Most Shared

Nektar stock drops after Pfizer pulls plug on drug

Thu Oct 18, 2007 8:29am EDT

Stocks

   

BOSTON, Oct. 18 (Reuters) - Shares of Nektar Therapeutics (NKTR.O) fell 22 percent on Thursday in premarket trading after its partner Pfizer Inc. (PFE.N) returned the rights to their inhaled diabetes drug Exubera amid sluggish sales.

Exubera, which was developed by Nektar and Pfizer, was approved by U.S. regulators in January 2006. The hope was that diabetics who require insulin would prefer to inhale it than inject it.

"Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians," Pfizer Chief Executive Jeff Kindler said in a statement. "We have therefore concluded that further investment in this product is unwarranted."

Nektar's shares fell to $6.30 in electronic trading before the market opened from a close of $8.08 on Wednesday on Nasdaq. (Reporting by Toni Clarke)



More from Reuters

Fannie Mae says adopts new pay rules

(Reuters) - Fannie Mae said it has adopted new compensation arrangements for executive officers, according to a filing with the Securities and Exchange Commission on Thursday.

» More Top News
Senate Majority Leader Harry Reid (D-NV) (C) walks with Senator Christopher Dodd (D-CT) (R) and Senator Max Baucus (D-MT) after the U.S. Senate approved President Barack Obama's healthcare overhaul on Capitol Hill in Washington, December 24, 2009. REUTERS/Jim Young

Reid delivers on healthcare

Party-line Senate vote passes bill that would extend health coverage to tens of millions of uninsured Americans, but it's not law yet.  Full Article 

Healthcare Reform
A security guard walks past cars in a Geely Automobile Holdings Ltd. factory in a Shanghai suburb September 28, 2006.REUTERS/Aly Song
WEI GU:

China in auto power play

It might not shake up the industry just yet, but China's interest in Volvo and Saab is the start of something big in global autos.  Commentary | Video 

CHINA